CoDa Therapeutics Inc

CoDa Therapeutics Announces Positive Results from Phase 2b Study of NEXAGON® in Chronic Venous Leg Ulcers

January 8, 2013

CoDa Therapeutics, Inc. today announced positive results from a Phase 2b clinical trial of NEXAGON® in patients with chronic venous leg ulcers. NEXAGON® is an easy to administer, once-a-week, topical, drug candidate being developed for the treatment of chronic wounds. It is designed to increase the incidence of wound healing compared to existing therapeutic techniques, and to heal them much faster. The company believes these results support advancing NEXAGON into Phase 3 registration trials. Venous leg ulcers are increasingly common and costly, and can be a cause of prolonged suffering for patients...

More...

CoDa Therapeutics Completes $49 Million Fund Raising .

July 24, 2012

AUCKLAND – CoDa Therapeutics, Inc. announced today that it raised an additional NZ$24.5M from Russian investment firm RusnanoMedInvest (“RMI”). This brings the company’s total Series B Round to nearly NZ$49 million following a first close late last year...

More...

Square 1 Announces $6 Million Credit Facility to CoDa Therapeutics, Inc.

6 October 2011

SAN DIEGO – (BUSINESS WIRE) – Square 1 Bank, the exclusive banking partner to entrepreneurs and the venture capital community, is pleased to partner with CoDa Therapeutics, Inc. in providing a $6 million term loan. This financing comes on the heels of a recent $19 million fundraising that the company closed in April. CoDa Therapeutics is a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care, inflammation and tissue repair based on a new platform technology known as "Gap Junction Modulation." They are working on a drug therapy to address wounds that heal poorly, including venous leg and diabetic foot ulcers.

More...

CoDa Therapeutics Closes $19 Million Series B Financing Round

18 April 2011

San Diego, California - April 18, 2011 - CoDa Therapeutics, Inc. announced today that it has raised $19.2 million in a Series B financing. Current investors Domain Associates, GBS Venture Partners and BioPacificVentures participated in the round. The company expects further Series B financing with participation from additional investors in a second closing, scheduled for a future date.

More...

CoDa Therapeutics Appoints Chief Medical Officer

2 May 2011

San Diego, California – May 2, 2011 – CoDa Therapeutics, Inc. announced today that it has named David E. Eisenbud, MD, as CMO (Chief Medical Officer). The appointment of Dr. Eisenbud is key to the continuing development of novel targeted therapies that address major unmet medical needs in inflammation, wound-healing and tissue repair. The expansion of the management team follows the closing of a $19.2 million Series B financing round two weeks ago.

More...

CoDa Therapeutics Closes $19 Million Series B Financing Round

18 April 2011

San Diego, California - April 18, 2011 - CoDa Therapeutics, Inc. announced today that it has raised $19.2 million in a Series B financing. Current investors Domain Associates, GBS Venture Partners and BioPacificVentures participated in the round. The company expects further Series B financing with participation from additional investors in a second closing, scheduled for a future date.

More...

CoDa Therapeutics’ NEXAGON^® Wound Healing Gel Named to Windhover’s “Top 10 HOT SPACE Projects to Watch”

23 September 2010

San Diego, California, September 17, 2010 – CoDa Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care, tissue repair, and inflammation, today announced that its wound healing gel, NEXAGON^®, has been named one...
More...

CoDa Therapeutics Achieves Positive Phase 2 Efficacy of NEXAGON^® in Chronic Venous Leg Ulcers

31 May 2010

San Diego, California, May 25, 2010 – CoDa Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for wound care and tissue repair, today announced positive results from its Phase 2 NOVEL Study of NEXAGON® in patients with chronic venous leg ulcers...
More...

CoDa Therapeutics Receives Orphan Drug Designation for Nexagon^® for the Treatment of Persistent Corneal Epithelial Defects

11 May 2009

May 11. 2009 - CoDa Therapeutics, Inc. today announced that its lead drug product candidate, Nexagon^®, has received Orphan Drug Designation from the U.S Food and Drug Administration for the treatment of persistent corneal epithelial defects...
More...